Kuangda Technology: sign a 5.5 billion yuan filter chip R & D and production project

Clinical CRO Tigermed: The ‘Small and Beautiful’

In this race of pharmaceutical R&D outsourcing segment, WuXi AppTec, Pharmaron, Tigermed and Asychem are some of the major names – but which has a truly winning side?

CRO ClinChoice Raises USD 150 Mn in Series E Round

2015 is the inflection point for the development of China's innovative drug industry and CRO (clinical research organization). On July 22nd, 2015, after CDE (Center For Drug Evaluation) released the announcement on self-examination and verification of drug clinical trial data, the supervision of Chinese clinical trials moved towards standardization. The investment and financing of innovative drugs in China continued to increase, laying the foundation for the growth of CRO.

CRSC Wins Eight Significant Bids with Total Value of CNY 2.17 Bn

CRSC wins two bids on the railway system market and six bids on the urban railway market in recent two months, which is likely to help the company achieve growth again in Q4 2020 and fiscal year 2021.

CRO Giant Tigermed’s 1H 2020 Net Profits Up 98%

Chinese CRO industry is setting off – the continued pandemic may bring the most potential to this industry.

WuXi AppTec: A Favorable Chinese Stock for MSCI and FTSE Russell

According to the latest quarterly index review, a Wuxi-based CRO company will be incorporated into the FTSE China A 50 Share Index.  It has been considered a top holding by many MSCI China indexes for some time.